Peer-Reviewed Study Validates BrainCheck’s Digital Cognitive Test, Signaling Breakthrough for Future of Dementia Diagnosis
- S&P 500 ends higher as investors eye rate outlook
- Amazon to invest up to $4 billion in Anthropic amid AI arms race
- Microsoft (MSFT) has no more Sell ratings as Guggenheim upgrades, admits being 'dead wrong'
- Global share index slips as investors absorb 'higher-for-longer' rate outlook
- Buy Apple, Nvidia, Netflix and these other stocks on a pullback - Citi
Research paper published by Journal of Medical Internet Research Aging expands on the diagnostic accuracy of BrainCheck’s digital cognitive testing for dementia and remote versus in-person cognitive testing
HOUSTON & AUSTIN, Texas--(BUSINESS WIRE)-- BrainCheck Inc., creator of the comprehensive cognitive assessment and care management platform for physicians, announced the publication of a peer-reviewed study in the Journal of Medical Internet Research (JMIR) Aging: A Computerized Cognitive Test Battery for Detection of Dementia and Mild Cognitive Impairment: Instrument Validation Study.
Led by Dr. Reza Hosseini Ghomi, who at the time of the study was a neuropsychiatrist and faculty at the University of Washington Medicine Memory and Brain Wellness Center, the study validates the diagnostic accuracy of the BrainCheck computerized cognitive testing platform. The study found that BrainCheck was able to correctly distinguish between three levels of cognitive performance, including diagnosing dementia, mild cognitive impairment (MCI) and normal cognition (NC).
“The findings from this latest study, published in JMIR Aging, are a major step forward for dementia diagnosis and treatment,” Dr. Hosseini Ghomi, Chief Medical Officer of BrainCheck, said. “BrainCheck is committed to transforming the approach to cognitive care. By providing remote and clinic-based digital testing, the company is democratizing access to care, and offering providers the tools and resources they need to better diagnose and treat patients.”
Early dementia detection, intervention and care planning helps more patients live better and safer lives, decreases caregiver frustration and saves health systems billions of dollars. Remote testing through digitally-enabled tools make cognitive assessments more accessible and removes common barriers in the patient journey.
Study participants had all previously been diagnosed with dementia, MCI or NC and were asked to complete the BrainCheck battery to compare the resulting diagnosis. The study concluded that “BrainCheck was able to distinguish between diagnoses of dementia, MCI, and NC, providing a reliable tool for the detection of early cognitive impairment.” Importantly, remote administration performed similarly to in-person testing. This study was among the first to validate a digital tool for the identification of MCI, which is notoriously hard to detect. Several studies are planned to start this year to further validate this finding.
BrainCheck is automated and quick to administer, both in-person and remotely, which improves accessibility to testing and enables early detection of cognitive decline, a particularly prevalent issue within the US where one in 10 people age 65 and older have Alzheimer’s dementia, and an estimated 13.8 million Americans are projected to have Alzheimer’s dementia by 2050 (Alzheimer’s Association). This initial study paves the way for a comprehensive longitudinal study, exploring BrainCheck in early detection of dementia and monitoring of cognitive symptoms over time, including further comparison to gold-standard neuropsychological assessments.
For medical professionals interested to learn more about BrainCheck and request a demo click here.
BrainCheck provides rapid, mobile cognitive assessment and decision support technology to physicians, empowering them to deliver high-quality, personalized cognitive health care to patients everywhere and get reimbursed. This helps patients live better and safer lives at home, decreases caregiver frustration, and saves health systems trillions. Founded in 2015 by neuroscientists and technologists Drs. Yael Katz and David Eagleman, BrainCheck helps lessen the human and economic toll of cognitive impairment and dementia through its interactive cognitive assessment and care management technology. BrainCheck is used in over 400 clinical practices and by 150,000 people around the world to detect cognitive changes early and enable patients, caregivers, and clinicians to work together to implement personalized recommendations to preserve brain health and functional independence. BrainCheck enables physicians to get paid for cognitive care management (via Medicare reimbursement and risk-adjusted capitated payments) and simultaneously reduces healthcare costs by keeping patients healthy, safe, and out of the hospital. To learn more, please visit braincheck.com.
+1 408 482 3546
Source: BrainCheck Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Domo Recognized as One to Watch in Snowflake’s Modern Marketing Data Stack Report
- bebe stores, inc. Announces B. Riley’s Agreement to Purchase 3.7M bebe shares from Founder Manny Mashouf
- House of Web3 Welcomes Cutting Edge Immersive Theater Ensemble to the Bay Area
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!